Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT-SAB: Combination vs Monotherapy for S. Aureus Bacteremia
NCT07376889Phase 4Recruiting
- Sponsor
- Intermountain Health
- Start
- Feb 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ertapenem and ceftaroline fosamil in Staphylococcus aureus bacteremia (SAB) (4 arms), sponsored by Intermountain Health. Primary endpoint: Desirability of Outcome Ranking at 30 days. Started Feb 2026; status: recruiting.
02
Drugs
ertapenemceftaroline fosamil
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT07376889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376889.